No Interaction Expected
Emtricitabine/Tenofovir-DF (FTC/TDF, PrEP)
Quality of Evidence: Very Low
Coadministration with the emtricitabine/tenofovir-DF has not been studied. No significant interaction was observed following administration of emtricitabine alone (200 mg single dose) and stavudine (40 mg single dose) to 6 HIV-negative subjects. Similarly, no significant interaction was observed following administration of a single dose of the extended release formulation of stavudine (d4T-XR 100 mg) and tenofovir-DF (300 mg once daily). No dose modification is required.